An industry-sponsored survey of specialty physicians in America revealed that their awareness and perceptions of biosimilar drugs can be lacking in some areas, but they would be interested in learning more about the concept.
Researchers from the Biosimilars Forum surveyed 1201 American dermatologists, gastroenterologists, rheumatologists, nephrologists, hematology-oncologists, and medical oncologists who reported prescribing biologic drugs, and published the findings in the journal Advances in Therapy. The study was conducted from November 2015 to January 2016, which could contribute to the seemingly low levels of knowledge among the participants, since the first FDA-approved biosimilar had just entered the market in September 2015.
Some participants were seemingly confused about what defines a biologic, despite the fact that all participants reported they prescribed biologic drugs. Medical oncologists, for instance, correctly identified a given drug as a biologic 62.8% of the time. Similarly, the vast majority said they have heard about biosimilars, but knowledge of specifics was low.
Around half of respondents from each specialty correctly said that biosimilars had just become available in the United States within the past year, with the exception of rheumatologists, 55.5% of whom thought that biosimilars were not yet available in the country. While 62.3% of respondents knew that biosimilars must be equally efficient as the original drug and 57.2% said the biosimilar must be comparable in safety, over half (55.2%) disagreed that biosimilars were safe.
There was some confusion regarding the term “interchangeable,” which indicates that a biosimilar has demonstrated its safety and efficacy for back-and-forth switching with the original biologic. Four out of 5 respondents did not know that interchangeability would let pharmacists switch between the originator biologic and its biosimilar products.
Respondents also reported concerns about the approval process. Half were knowledgeable of the concept of “totality of evidence” used to assess biosimilars, and just 12% were comfortable with the concept of extrapolation to approve a biosimilar for other indications based on the originator biologic, although this could be due to knowledge gaps on what the term actually means.
Despite these apprehensions, 91% of respondents said they would be open to prescribing biosimilars to their patients after seeing sufficient evidence on switching and indications. They also indicated they would like to learn more about key biosimilars concepts and their potential impact on drug costs and access.
The study authors wrote that the survey results “highlight a significant need for evidence-based education about biosimilars for physicians across specialties.” They plan to conduct a follow-up survey in 2 to 3 years to examine whether awareness and perceptions about biosimilars have improved as new drugs continue to enter the US and European markets.
Reference
Cohen H, Beydoun D, Chien D, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2017;33(12):2160-2172.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Part 1: Unlocking the Potential of Biosimilars to Improve Health Equity
May 7th 2024Biosimilars offer a promising path to affordable, effective treatment, but barriers remain for underserved communities. This 2-part series explores the potential of biosimilars to improve health equity while addressing the obstacles that currently prevent access.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.